Table S3. The statistical analysis of the differential metabolites identified between the control group and the different treated groups.
| Metabolites | C-PANC | C-CUS-H | C-CUS-L | C-G | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ra | VIPb | Pc | FCd | r | VIP | P | FC | r | VIP | P | FC | r | VIP | P | FC | ||||
| 3-hydroxybutyrate | −0.808 | 3.238 | 1.9×10−3 | 0.59 | −0.751 | 4.120 | 1.4×10−4 | 0.44 | −0.794 | 3.483 | 1.3×10−4 | 0.44 | −0.785 | 3.892 | 1.8×10−3 | 0.54 | |||
| Acetone | 0.786 | 1.365 | 3.3×10−4 | 1.41 | –e | – | – | – | 0.762 | 1.089 | 6.2×10−4 | 1.35 | – | – | – | – | |||
| Allantoin | −0.907 | 1.270 | 2.7×10−2 | 0.74 | – | – | – | – | −0.861 | 1.013 | 3.5×10−2 | 0.80 | −0.936 | 1.389 | 1.6×10−2 | 0.78 | |||
| Ascorbate | −0.650 | 1.067 | 2.8×10−2 | 0.60 | −0.743 | 1.387 | 6.5×10−4 | 0.28 | −0.665 | 1.086 | 7.1×10−3 | 0.49 | – | – | – | – | |||
| Citrate | – | – | – | – | −0.871 | 1.872 | 6.0×10−4 | 0.83 | −0.869 | 1.762 | 7.0×10−4 | 0.81 | – | – | – | – | |||
| Creatine | −0.825 | 3.605 | 6.8×10−3 | 0.83 | – | – | – | – | −0.823 | 2.379 | 4.5×10−2 | 0.87 | – | – | – | – | |||
| Dimethylamine | 0.885 | 1.599 | 6.2×10−5 | 2.15 | 0.983 | 1.883 | 5.1×10−14 | 2.14 | 0.979 | 1.547 | 5.4×10−15 | 2.23 | 0.982 | 1.955 | 4.4×10−11 | 2.19 | |||
| Ethanol | – | – | – | – | – | – | – | – | −0.674 | 1.265 | 2.7×10−2 | 0.88 | – | – | – | – | |||
| Glutamate | – | – | – | – | 0.780 | 1.324 | 2.2×10−3 | 1.14 | – | – | – | – | – | – | – | – | |||
| Gly | – | – | – | – | 0.779 | 4.980 | 4.1×10−2 | 1.23 | 0.907 | 7.408 | 4.2×10−3 | 1.30 | – | – | – | – | |||
| HDL | −0.824 | 0.904 | 1.7×10−5 | 0.52 | – | – | – | – | – | – | – | – | −0.875 | 1.101 | 8.1×10−7 | 0.39 | |||
| Histidine | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |||
| Isobutyrate | −0.794 | 1.116 | 1.3×10−3 | 0.71 | – | – | – | – | −0.794 | 1.064 | 5.9×10−5 | 0.59 | −0.791 | 1.300 | 6.7×10−4 | 0.65 | |||
| Isoleucine | – | – | – | – | – | – | – | – | 0.798 | 1.298 | 2.0×10−2 | 1.18 | – | – | – | – | |||
| Lactate | −0.849 | 13.92 | 3.3×10−4 | 0.76 | – | – | – | – | −0.881 | 14.402 | 2.1×10−5 | 0.72 | – | – | – | – | |||
| Leucine | – | – | – | – | 0.731 | 1.851 | 1.1×10−3 | 1.27 | 0.753 | 1.457 | 2.2×10−3 | 1.21 | 0.624 | 1.954 | 3.4×10−2 | 1.19 | |||
| Lipid | – | – | – | – | 0.976 | 2.552 | 3.2×10−3 | 1.25 | 0.991 | 2.319 | 4.3×10−4 | 1.27 | – | – | – | – | |||
| LDL | – | – | – | – | 0.741 | 3.504 | 2.5×10−4 | 1.22 | 0.751 | 3.219 | 9.2×10−4 | 1.19 | 0.678 | 3.011 | 1.5×10−2 | 1.15 | |||
| Lysine | – | – | – | – | 0.960 | 1.961 | 2.6×10−3 | 1.13 | 0.860 | 1.126 | 4.4×10−2 | 1.08 | – | – | – | – | |||
| Methanol | 0.887 | 1.700 | 3.7×10−6 | 1.54 | 0.855 | 1.764 | 2.2×10−6 | 1.54 | 0.849 | 1.490 | 3.8×10−7 | 1.54 | 0.912 | 1.769 | 6.1×10−3 | 1.55 | |||
| Methionine | −0.755 | 1.821 | 1.2×10−2 | 0.88 | 0.859 | 2.720 | 2.1×10−3 | 1.19 | 0.925 | 1.447 | 2.6×10−2 | 1.11 | – | – | – | – | |||
| myo-Inositol | 0.843 | 1.640 | 1.0×10−2 | 1.11 | – | – | – | – | 0.871 | 2.750 | 2.3×10−4 | 1.18 | 0.841 | 2.182 | 3.9×10−2 | 1.12 | |||
| Phosphocholine | – | – | – | – | – | – | – | – | 0.788 | 2.999 | 5.3×10−3 | 1.18 | – | – | – | – | |||
| Pyruvate | −0.682 | 3.182 | 1.7×10−2 | 0.76 | −0.768 | 3.817 | 7.3×10−5 | 0.51 | −0.827 | 3.060 | 4.4×10−4 | 0.59 | −0.782 | 3.111 | 1.3×10−2 | 0.75 | |||
| Sarcosine | 0.818 | 1.638 | 2.4×10−4 | 2.28 | 0.982 | 1.874 | 8.1×10−13 | 2.32 | 0.975 | 1.576 | 5.0×10−14 | 2.29 | 0.978 | 1.932 | 1.0×10−6 | 2.32 | |||
| Serine | – | – | – | – | 0.779 | 1.459 | 7.2×10−4 | 1.23 | 0.843 | 1.238 | 1.3×10−3 | 1.18 | 0.713 | 1.163 | 4.3×10−2 | 1.11 | |||
| Succinate | −0.807 | 2.957 | 4.6×10−5 | 0.56 | −0.775 | 2.921 | 3.5×10−5 | 0.55 | −0.865 | 2.951 | 1.5×10−5 | 0.51 | −0.692 | 2.576 | 4.8×10−3 | 0.70 | |||
| Threonine | 0.914 | 1.101 | 3.3×10−3 | 1.81 | – | – | – | – | – | – | – | – | – | – | – | – | |||
| Trimethylamine | – | – | – | – | – | – | – | – | 0.910 | 1.216 | 3.9×10−4 | 1.87 | – | – | – | – | |||
| Trimethylamine N-oxide | – | – | – | – | 0.682 | 0.711 | 1.9×10−2 | 1.17 | – | – | – | – | 0.774 | 1.009 | 1.5×10−3 | 1.26 | |||
| VLDL | 0.900 | 2.692 | 5.1×10−5 | 2.10 | – | – | – | – | 0.953 | 2.097 | 1.2×10−7 | 2.04 | 0.932 | 2.904 | 6.2×10−3 | 1.59 | |||
| α-glucose | – | – | – | – | −0.743 | 3.617 | 3.4×10−3 | 0.78 | – | – | – | – | – | – | – | – | |||
| β-glucose | −0.734 | 4.074 | 3.5×10−3 | 0.80 | −0.874 | 5.342 | 3.4×10−6 | 0.63 | – | – | – | – | −0.843 | 5.143 | 5.1×10−4 | 0.73 | |||
a, correlation coefficients, positive and negative signs indicate positive and negative correlation in the concentrations, respectively. The cutoff value of correlation coefficient for the statistical significance was based on their respective discrimination significance at the level of P=0.05 and degree of freedom. b, variable importance in projection. The VIP values at the top of 20% of all VIP scores were used as the cutoff values for the statistical significance. c, the P values were transformed by the values Student’s t-test. The P values less than 0.05 were used as the cutoff values for the statistical significance. d, fold change, the concentration ratio between the pair-wise groups. e, any one parameter in correlation coefficient, VIP value and P value is unqualified for the statistical significance. C, control group; PANC, pancreatic cancer mice; CUS-H, high-dosage cucurmosin treated mice with pancreatic cancer; CUS-L, low-dosage cucurmosin treated mice with pancreatic cancer; G, gemcitabine-treated mice with pancreatic cancer; VIP, variable importance for the projection.